Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 72% 330 → 91 participants
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 263 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Enrollment increased: 91 → 118 participants
  2. Eligibility criteria expanded, about 17 words
    • Study description expanded, about 20 words
    • Publications shortened, about 48 words
  3. 5 versions Re-verified since Aug 15, 2026, no change to tracked fieldsv257-v261
  4. Enrollment reduced: 330 → 91 participants
    • Enrollment closed, study ongoing
    • Site details revised at 2 of 2 sites
    v256
  5. 4 versions Re-verified since Jun 27, 2026, no change to tracked fieldsv252-v255
  6. Primary completion pushed from Oct 31, 2026 to Jun 1, 2027v251
  7. 20 versions Re-verified since May 17, 2025, no change to tracked fieldsv231-v250
  8. Eligibility criteria revisedv230
  9. 2 versions Re-verified since May 3, 2025, no change to tracked fieldsv228-v229
  10. Eligibility criteria shortened, about 56 wordsv227
  11. Primary completion date: Jun 30, 2025 to Oct 31, 2026
    • Study completion date: Jun 30, 2029 to Oct 31, 2030
    v226
  12. 6 versions Re-verified since Jan 28, 2025, no change to tracked fieldsv220-v225
  13. Eligibility criteria shortened, about 3 words
    • Study description expanded, about 2 words
    v219
  14. 3 versions Re-verified since Nov 30, 2024, no change to tracked fieldsv216-v218
  15. Eligibility criteria shortened, about 30 wordsv215
  16. Re-verified, no change to tracked fieldsv214
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test if new ways of getting a recipient ready for a transplant may result in fewer problems and side effects. Eligibility: Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to standard treatments Donors: Healthy people ages 18 and older whose relative has lymphoma Design: Participants will be screened with: Physical exam Blood and urine tests Bone marrow biopsy: A needle inserted into the participant s hip bone will remove marrow. Donors will also be screened with: X-rays Recipients will also be screened with: Lying in scanners that take pictures of the body Tumor sample Donors may donate blood. They will take daily shots for 5 7 days. They will have apheresis: A machine will take blood from one arm and take out their stem cells. The blood will be returned into the other arm. Recipients will be hospitalized at least 2 weeks before transplant. They will get a catheter: A plastic tube will be inserted into a vein in the neck or upper chest. They will get antibody therapy or chemotherapy. Recipients will get the transplant through their catheter. Recipients will stay in the hospital several weeks after transplant. They will get blood transfusions. They will take drugs including chemotherapy for about 2 months. Recipients will have visits 6, 12, 18, 24 months after transplant, then once a year for 5 years.
Trial Details
NCT Number NCT03922724
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Related terms Autoimmune Diseases, Immune System Diseases, Lymphoma, T-Cell, Peripheral, Lymphoproliferative Disorders, Opportunistic Infections
Enrollment 118 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov